1421314-64-8

Upstream product

• 61160-18-7 3-benzyloxy-2-methyl-1H-pyridin-4-one 
• 100-39-0 benzyl bromide 
• 118-71-8 Maltol 
• 61049-69-2 3-O-benzylmaltol 

Downstream Products

• 1421314-65-9 5-benzyloxy-4-hydroxy-6-methyl-nicotinic acid methyl ester 
• 906658-35-3 5-benzyloxy-4-hydroxy-6-hydroxymethyl-nicotinic acid 
• 906657-88-3 methyl 4-acetoxy-5-benzyloxy-6-methylnicotinate 
• 906657-89-4 methyl 4-acetoxy-5-benzyloxy-6-methyl-1-oxynicotinate 
• 906657-90-7 methyl 4-acetoxy-6-acetoxymethyl-5-benzyloxynicotinate 
• 1421314-67-1 5-benzyloxy-N-(4-fluoro-benzyl)-6-formyl-4-hydroxy-nicotinamide 
• 906657-92-9 5-benzyloxy-N-(4-fluoro-benzyl)-4-hydroxy-6-hydroxymethyl-nicotinamide 
• 906657-95-2 3-benzyloxy-5-(4-fluoro-benzylcarbamoyl)-4-hydroxy-pyridine-2-carboxylic acid 
• 1421314-68-2 3-benzyloxy-5-(4-fluoro-benzylcarbamoyl)-4-hydroxy-pyridine-2-carboxylic acid methyl ester 
• 906657-98-5 methyl 3-(benzyloxy)-5-((4-fluorobengzyl)carbamoyl)-4-oxo-1-(2-oxoethyl)-1,4-dihydropyridine-2-carboxylate 
• 906657-97-4 methyl 1-allyl-3-benzyloxy-5-(4-fluorobenzylcarbamoyl)-4-oxo-1,4-dihydropyridine-2-carboxylate 
• 906657-99-6 9-benzyloxy-2-(2-methoxyethyl)-1,8-dioxo-1,8-dihydro-2H-pyrid[1,2-a]pyrazine-7-carboxylic acid 4-fluorobenzylamide 
• 906657-93-0 C₂₇H₂₂FN₅O₄ 
• 1421314-67-1 5-benzyloxy-N-(4-fluorobenzyl)-6-formyl-4-oxo-1,4-dihydropyridine-3-carboxamide 

Relevant academic research and scientific papers

The synthesis of 5-functional 3-hydroxypyridin-4-ones and their impact on the chelating properties of the ligands

The presence of the 5-functional group on 3-hydroxypyridin-4-ones (HPOs) can significantly change their chelating properties because the 5-position is adjacent to one of the chelating moieties. A 5-methoxy-substituted HPO has been successfully synthesized using a 5-bromo analogue with NaOMe in the presence of a copper(I) catalyst. The atomic charges and stability constants of the HPOs with either electron-donating or election-withdrawing groups on the 5-position were compared. The result showed that the 5-substituted HPOs possess lower stability constants, compared to those of the 5-unsubstituted analogue (deferiprone).

Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles

This work is a continuation of our initial discovery of a potent monocyclic carbamoyl pyridone human immunodeficiency virus type-1 (HIV-1) integrase inhibitor that displayed favorable antiviral and pharmacokinetic properties. We report herein a series of

TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as m PGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (m PGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY

The present invention is to provide a novel compound (I), having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. Compound (I) wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4 and Z2 part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.